https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=28815034&retmode=xml&tool=Litmetric&email=readroberts32@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09 2881503420191120
2050-6406552017AugUnited European gastroenterology journalUnited European Gastroenterol JCompliance with the faecal calprotectin test in patients with inflammatory bowel disease.702707702-70710.1177/2050640616686517We investigated, for the first time, levels of compliance with faecal calprotectin test in inflammatory bowel disease patients.All consecutive adult inflammatory bowel disease patients having been prescribed an faecal calprotectin test between December 2014-July 2015 were included. At their next visit to the hospital, patients had to return a stool sample for the faecal calprotectin test and answer a simple questionnaire: 'Have you brought a stool sample? If not, why not? If so, did you encounter any difficulties when collecting the sample? Were you aware of faecal calprotectin before being asked to take the test?'.One hundred and one patients were included (50 men; 77 patients with Crohn's disease). The range age was 40 years (19-68). Eighty-nine patients were being treated with infliximab, 10 were on vedolizumab, and two were not being treated with a biologic. Thirty-seven patients (35%) had performed the faecal calprotectin test. Eighty-one patients (80%) had not been aware of faecal calprotectin before being asked to take the test. Of the 64 patients who did not take the test, the prime reasons for non-compliance were forgetfulness (n = 49, 76.6%), a lack of perceived benefit for the test (n = 7, 11%), constipation (n = 5, 7.8%), refusal to handle faeces (n = 2, 3.1%), and difficulty collecting the stool sample (n = 1, 1.5%).Only one-third of the patients performed the faecal calprotectin test. The main reason for non-compliance was forgetfulness. Our present results emphasise the need for better patient education on the importance of complying with faecal calprotectin testing and the future of faecal calprotectin testing at home.MaréchalChloéCINSERM U954, Nancy University Hospital, Nancy, France.Department of Hepatogastroenterology, Nancy University Hospital, Nancy, France.Aimone-GastinIsabelleIDepartment of Biochemistry, Nancy University Hospital, Nancy, France.BaumannCédricCPARC Clinical Research Support Facility, Nancy University Hospital, Nancy, France.DirrenbergerBastienBINSERM U954, Nancy University Hospital, Nancy, France.Department of Hepatogastroenterology, Nancy University Hospital, Nancy, France.GuéantJean-LouisJLINSERM U954, Nancy University Hospital, Nancy, France.Department of Biochemistry, Nancy University Hospital, Nancy, France.Peyrin-BirouletLaurentLINSERM U954, Nancy University Hospital, Nancy, France.Department of Hepatogastroenterology, Nancy University Hospital, Nancy, France.engJournal Article20170206
EnglandUnited European Gastroenterol J1016068072050-6406Inflammatory bowel diseasecompliancefaecal calprotectin2016892016123201781860201781860201781861201781ppublish28815034PMC554835610.1177/205064061668651710.1177_2050640616686517Baumgart DC, Sandborn WJ. Inflammatory bowel disease: Clinical aspects and established and evolving therapies. Lancet 2007; 369: 1641–1657.17499606Peyrin-Biroulet L, Ferrante M, Magro F, et al. Results from the 2nd scientific workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis 2011; 5: 477–483.21939925Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease. Inflamm Bowel Dis 2009; 15: 1295–1301.19340881D’Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: An open randomised trial. Lancet 2008; 371: 660–667.18295023Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: Data from the EXTEND trial. Gastroenterology 2012; 142: 1102–1111.22326435Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462–2476.16339095Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): Determining therapeutic goals for treat-to-target. Am J Gastroenterol 2015; 110: 1324–1338.26303131Annese V, Daperno M, Rutter MD, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis 2013; 7: 982–1018.24184171Dubé C. Minor adverse events postcolonoscopy. Can J Gastroenterol Hepatol 2014; 28: 606–606.PMC427717425575110Lüning TH, Keemers-Gels ME, Barendregt WB, et al. Colonoscopic perforations: A review of 30,366 patients. Surg Endosc 2007; 21: 994–997.17453289Svensson MH, Svensson E, Lasson A, et al. Patient acceptance of CT colonography and conventional colonoscopy: Prospective comparative study in patients with or suspected of having colorectal disease. Radiology 2002; 222: 337–345.11818597Mosli MH, Zou G, Garg SK, et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: A systematic review and meta-analysis. Am J Gastroenterol 2015; 110: 802–819.25964225Benitez J-M, Meuwis M-A, Reenaers C, et al. Role of endoscopy, cross-sectional imaging and biomarkers in Crohn’s disease monitoring. Gut 2013; 62: 1806–1816.24203056Kopylov U, Rosenfeld G, Bressler B, et al. Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease. Inflamm Bowel Dis 2014; 20: 742–756.24562174Langhorst J, Elsenbruch S, Koelzer J, et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: Performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008; 103: 162–169.17916108Gisbert JP, Bermejo F, Pérez-Calle J-L, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 2009; 15: 1190–1198.19291780Røseth AG, Fagerhol MK, Aadland E, et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992; 27: 793–798.1411288Saverymuttu SH, Peters AM, Crofton ME, et al. 111Indium autologous granulocytes in the detection of inflammatory bowel disease. Gut 1985; 26: 955–960.PMC14328694029721Lin J-F, Chen J-M, Zuo J-H, et al. Meta-analysis: Fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis 2014; 20: 1407–1415.24983982Mao R, Xiao Y, Gao X, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: A meta-analysis of prospective studies. Inflamm Bowel Dis 2012; 18: 1894–1899.22238138D’Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 2218–2224.22344983De Vos M, Louis EJ, Jahnsen J, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis 2013; 19: 2111–2117.23883959Naismith GD, Smith LA, Barry SJE, et al. A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn’s disease. Aliment Pharmacol Ther 2013; 37: 613–621.23347334Moum B, Jahnsen J, Bernklev T. Fecal calprotectin variability in Crohn’s disease. Inflamm Bowel Dis 2010; 16: 1091–1092.19834972Wright EK, Kamm MA, De Cruz P, et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn’s disease after surgery. Gastroenterology 2015; 148: 938–947.e1.25620670Boschetti G, Laidet M’harid, Moussata D, et al. Levels of fecal calprotectin are associated with the severity of postoperative endoscopic recurrence in asymptomatic patients with Crohn’s disease. Am J Gastroenterol 2015; 110: 865–872.25781366Ferreiro-Iglesias R, Barreiro-de Acosta M, Otero Santiago M, et al. Fecal calprotectin as predictor of relapse in patients with inflammatory bowel disease under maintenance infliximab therapy. J Clin Gastroenterol 2016; 50: 147–151–147–151.25811118Macrae FA, St John DJ, Ambikapathy A, et al. Factors affecting compliance in colorectal cancer screening. Results of a study performed in Ballarat. Med J Aust 1986; 144: 621–623.3713601Mant D, Fuller A, Northover J, et al. Patient compliance with colorectal cancer screening in general practice. Br J Gen Pract 1992; 42: 18–20.PMC13719621586526Lopez A, Billioud V, Peyrin-Biroulet C, et al. Adherence to anti-TNF therapy in inflammatory bowel diseases: A systematic review. Inflamm Bowel Dis 2013; 19: 1528–1533.23518810Vangeli E, Bakhshi S, Baker A, et al. A systematic review of factors associated with non-adherence to treatment for immune-mediated inflammatory diseases. Adv Ther 2015; 32: 983–1028.PMC466272026547912Bramley TJ, Gerbino PP, Nightengale BS, et al. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm 2006; 12: 239–245.PMC1043794016623608Giorda C, Picariello R, Nada E, et al. The impact of adherence to screening guidelines and of diabetes clinics referral on morbidity and mortality in diabetes. PloS One 2012; 7: e33839–e33839.PMC331793322509263Burkhart PV, Sabaté E. Adherence to long-term therapies: Evidence for action. J Nurs Scholarsh 2003; 35: 207–207.14562485Jackson CA, Clatworthy J, Robinson A, et al. Factors associated with non-adherence to oral medication for inflammatory bowel disease: A systematic review. Am J Gastroenterol 2010; 105: 525–539.19997092Armuzzi A, Gionchetti P, Daperno M, et al. Expert consensus paper on the use of vedolizumab for the management of patients with moderate-to-severe inflammatory bowel disease. Dig Liver Dis 2016; 48: 360–370–360–370.26821929Coorevits L, Baert FJ, Vanpoucke HJM. Faecal calprotectin: Comparative study of the Quantum Blue rapid test and an established ELISA method. Clin Chem Lab Med 2013; 5: 825–831.23001318Ogedegbe G, Schoenthaler A. A systematic review of the effects of home blood pressure monitoring on medication adherence. J Clin Hypertens (Greenwich) 2006; 8: 174–180.PMC810934816522994Depont F, Berenbaum F, Filippi J, et al. Interventions to improve adherence in patients with immune-mediated inflammatory disorders: A systematic review. PloS One 2015; 10: e0145076–e0145076.PMC469119626674526Viguier J, Calazel-Benque A, Eisinger F, et al. Organized colorectal cancer screening programmes: How to optimize efficiency among general practitioners. Eur J Cancer Prev 2011; 20: S26–S32.21245677